Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 3,737–3,744 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Roche Holding AG ADR GB1211 in combination with Tecentriq (atezolizumabe) - (GALLANT-1) Non-small cell lung cancer (NSCLC) Phase 2a Trial Completed Intravenous Oncology
Roche Holding AG ADR GB1211 in combination with Tecentriq (atezolizumabe) - (GALLANT-1) Non-small cell lung cancer (NSCLC) Phase 2a Trial Completed Intravenous Oncology
Rocket Pharmaceuticals Inc. KRESLADI (marnetegragene autotemcel) Leukocyte Adhesion Deficiency-I (LAD-I) PDUFA Ongoing Intravenous infusion Genetic Disorder
Rocket Pharmaceuticals Inc. RP-L102 Fanconi Anemia (FA) BLA Filing Ongoing Intravenous Genetic Disorder
Rocket Pharmaceuticals Inc. Trabodenoson Primary open-angle glaucoma (POAG) Phase 3 Trial Discontinued Ophthalmic Opthalmic
Rocket Pharmaceuticals Inc. RP-L301 Pyruvate Kinase Deficiency (PKD) Phase 2 Ongoing Intravenous Genetic Disorder
Rocket Pharmaceuticals Inc. RP-A501 Danon disease Phase 2 Hold Removed Intravenous Genetic Disorder
Rocket Pharmaceuticals Inc. Trabodenoson and latanoprost Glaucoma Phase 2 Trial Discontinued Ocular Opthalmic
1…466467468469470…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.